Cb Scientific Inc Stock Price, News & Analysis

CB Scientific announced the successful completion of its annual audit by MaloneBailey, LLP, adhering to PCAOB standards. This milestone positions the company strongly for an uplisting to the OTCQB Venture Market, expected to enhance investor benefits through higher reporting standards and improved analyst coverage. The company is also set to implement corporate changes, including a name change and relocation to Nevada, to facilitate future fundraising and a potential listing on the Nasdaq Capital Markets. These developments follow a shareholder mandate from a recent special meeting.

CB Scientific, Inc. (CBSC) successfully held its Special Meeting of Stockholders on January 14, 2022, achieving approximately 73% approval for all five proposals. The approved measures include reincorporating the company from Oregon to Nevada and renaming it Cardiac Biotech Solutions, Inc.. Management emphasizes this endorsement is crucial for pursuing future business goals and positions the company for a possible Nasdaq listing. The increase in common shares and potential reverse stock split will help maintain compliance with listing standards.

CB Scientific, Inc. (CBSC) will hold a Special Meeting of Stockholders on January 14, 2022, at 10:00 a.m. EST in Columbus, Ohio, focusing on pivotal corporate changes. Key proposals include a name change to better reflect business direction, relocating for favorable tax laws, increasing authorized shares for fundraising, and ratifying the 2021 Omnibus Stock Incentive Plan to attract talent. These measures aim to position CBSC for a potential Nasdaq listing. The record date for stockholders eligible to vote is December 23, 2021.

CB Scientific, Inc. (OTC PINK:CBSC) has initiated the Beta testing phase for its upgraded My-Cam cardiac event monitor. The new design boasts enhanced power consumption, improved lead wire shielding, and better signal quality, all while reducing costs. With increasing demand for the My-Cam device, the company aims to address supply chain challenges effectively. Following successful Beta testing, CBSC plans to enter Pre-production testing soon. The company will keep stakeholders informed of further developments through press releases and regulatory filings.

CB Scientific (OTC PINK:CBSC) has announced a partnership with Shenzhen Pump Medical System Co., Ltd. to manufacture medical products aimed at the Southeast Asian market. This collaboration is crucial for establishing local manufacturing capabilities and securing necessary FDA and NMPA approvals. CEO Charles Martin emphasized the importance of this relationship for regulatory validation and gaining access to regional distribution channels. The company plans to provide updates on future developments to shareholders and the public.

CB Scientific Inc. (OTC PINK:CBSC) announced a Special Stockholder Meeting to approve enhancements aimed at positioning the company for growth. The meeting will address a corporate name change, relocation for tax advantages, increased authorized shares for fundraising, and a ratification of the 2021 Omnibus Stock Incentive Plan. Management believes recent progress in Southeast Asia and an application to up list to the OTCQB creates the momentum needed for these changes. Details on the meeting date will be provided in the coming weeks.

CB Scientific (OTC PINK:CBSC) announced its application for uplisting to the OTCQB Venture Market. This move is aimed at enhancing trading efficiency and transparency. While the submission does not guarantee acceptance, the company has completed necessary steps, including a PCAOB audit and appointing independent directors. CEO Charles Martin emphasized that uplisting would position CBSC better for future goals, including a potential shift to Nasdaq. The company anticipates that uplisting will lead to improved compliance, reporting standards, and analyst coverage.

CB Scientific Inc. (OTC PINK:CBSC) has appointed Brooke Martellaro as its new Chief Financial Officer, effective immediately. Martellaro brings extensive experience from various corporations, enhancing the company's executive management. Her immediate focus includes collaborating with MaloneBailey LLP to conclude a PCAOB audit, vital for CBSC’s transition to the OTCQB Venture Market. The company emphasizes that Martellaro's financial expertise will significantly contribute to strategic and operational improvements, facilitating long-term success.

CB Scientific has appointed Paul K. Danner as Chairman of its Board of Directors, effective immediately. Danner brings over 25 years of experience with Nasdaq-listed companies. His leadership aims to enhance the company’s executive team amid plans for a timely uplist to the OTCQB Venture Market, pending a completed audit by MaloneBailey LLP. Danner expressed excitement about the company’s growth potential, focusing on expanding both domestically and internationally. CB Scientific provides innovative cardiac monitoring solutions, emphasizing their commitment to transparency with future announcements.